Corporate Information – Page 11 – Alligator Bioscience

2022-11-01

Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences

Lund, Sweden, November 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives wi ...

2022-10-24

Lund, Sweden, October 24, 2022– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...

2022-10-17

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) will host a conference call (in English) for investors, analysts and media ...

2022-10-10

Lund, Sweden, October 10, 2022 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announced that Mattias Levin, PhD, Sr Team Ma ...

2022-09-30

• ATOR-1017 demonstrated excellent safety and tolerability at doses up to 900 mg • Stable disease as best tumor response reconfirms previous ...

2022-09-192022-09-19

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. Lun ...

2022-09-14

Data from Phase 1b dose escalation part of the study shows that mitazalimab combined with mFOLFIRINOX is safe and well tolerated 900 µg/kg d ...

2022-09-06

Lund, Sweden, September 6, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives w ...

2022-05-31

ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...